ScholarIQanswers from OpenAlex & ORCID
Nong Yang
ResearcherPublications, citations & collaboration network
Nong Yang is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Nong Yang have?
ScholarIQindexed works
Nong Yang has 253 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Nong Yang have?
ScholarIQcitation count
Nong Yang has 7,287 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Nong Yang?
ScholarIQh-index
Nong Yang has an h-index of 39 in OpenAlex.
What is the i10-index of Nong Yang?
ScholarIQi10-index
Nong Yang has an i10-index of 103 in OpenAlex.
What is the ORCID of Nong Yang?
ScholarIQorcid
The ORCID for Nong Yang is on the source record.
What is the OpenAlex record for Nong Yang?
ScholarIQopenalex
The OpenAlex for Nong Yang is on the source record.
What are the most-cited papers on Nong Yang?
ScholarIQmost cited works
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen, Niels Reinmuth, Katsuyuki Hotta, Dmytro Trukhin, Galina Statsenko, Maximilian J. Hochmair, Mustafa Özgüroğlu, Jun Ho Ji, Marina Chiara Garassino, Олександр Войтко, Artem Poltoratskiy, Santiago Ponce, Francesco Verderame, Libor Havel, Igor Bondarenko, Andrzej Każarnowicz, György Losonczy, Nikolay Conev, J. Armstrong, Natalie Byrne, Piruntha Thiyagarajah, Haiyi Jiang, Luis Paz‐Ares, Mikhail Dvorkin, Dmytro Trukhin, Galina Statsenko, Nataliia Voitko, Artem Poltoratskiy, Igor Bondarenko, Yuanbin Chen, Andrzej Każarnowicz, Luis Paz‐Ares, Mustafa Özgüroğlu, Nikolay Conev, Maximilian J. Hochmair, Otto C. Burghuber, Libor Havel, İrfan Çiçin, György Losonczy, В. Моисеенко, Mustafa Erman, Dariusz M. Kowalski, Marek Z. Wojtukiewicz, Hryhoriy Adamchuk, Alexander Vasilyev, Serhii Shevnia, Spartak Valev, Niels Reinmuth, Jun Ho Ji, Maria Amelia Insa Molla, Grygorii Ursol, Anne C. Chiang, Sylvia Hartl, Zsolt Horváth, Gábor Pajkos, Francesco Verderame, Katsuyuki Hotta, Sang‐We Kim, Alexey Smolin, Tuncay Göksel, Shaker R. Dakhil, Jaromı́r Roubec, Krisztina Bogos, Marina Chiara Garassino, Robin Cornelissen, Jong-Seok Lee, M.R. García Campelo, Marta López Brea, Ahmet Alacacıoğlu, Ignacio Casarini, Rumyana Ilieva, Ivan Tonev, A Somfay, Jair Bar, Alona Zer Kuch, Mauro Minelli, Roberta Bartolucci, Fausto Roila, Haruhiro Saito, Koichi Azuma, Gyeong‐Won Lee, Alexander Luft, Michal Urda, Juan Ignacio Delgado Mingorance, M. Majem Tarruella, David R. Spigel, Krassimir Koynov, Milada Zemanová, Jens Panse, Christian Schulz, Zsolt Pápai Székely, Veronika Sárosi, Angelo Delmonte, Anna Bettini, Makoto Nishio, Isamu Okamoto, Lizza Hendriks, Sławomir Mańdziuk
Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients
Zhe Yang, Nong Yang, Qiuxiang Ou, Yi Xiang, Tao Jiang, Xue Wu, Hua Bao, Xiaoling Tong, Xiaonan Wang, Yang Shao, Yunpeng Liu, Yan Wang, Caicun Zhou
Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer
Jie Wang, Shun Lü, Xinmin Yu, Yanping Hu, Yuping Sun, Zhijie Wang, Jun Zhao, Yan Yu, Chunhong Hu, Kunyu Yang, Guosheng Feng, Kejing Ying, Wu Zhuang, Jianying Zhou, Jingxun Wu, Shiang Jiin Leaw, Jing Zhang, Xiao Lin, Liang Liang, Nong Yang
Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)
Yunpeng Yang, Zhehai Wang, Jian Fang, Qitao Yu, Baohui Han, Shundong Cang, Gongyan Chen, Xiaodong Mei, Zhixiong Yang, Rui Ma, Minghong Bi, Xiubao Ren, Jianying Zhou, Baolan Li, Yong Song, Jifeng Feng, Juan Li, Zhiyong He, Rui Zhou, Weimin Li, You Lü, Yingyi Wang, Lijun Wang, Nong Yang, Yan Zhang, Zhuang Yu, Yanqiu Zhao, Conghua Xie, Ying Cheng, Hui Zhou, Shuyan Wang, Donglei Zhu, Wen Zhang, Li Zhang
Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non–Small Cell Lung Cancer
Shun Lü, Wei Zhang, Lin Wu, Wenxiang Wang, Peng Zhang, Neotorch Investigators, Wentao Fang, Wenqun Xing, Qixun Chen, Lin Yang, Jiandong Mei, Lijie Tan, Xiaohong Sun, Shidong Xu, Xiaohua Hu, Guohua Yu, Dongliang Yu, Nong Yang, Yuping Chen, Jinlu Shan, Ligang Xing, Hui Tian, Xun Zhang, Ming Zhou, Haohui Fang, Guowu Wu, Yunpeng Liu, Minhua Ye, Lejie Cao, Jie Jiang, Xingya Li, Liangming Zhu, Shanqing Li, Mingqiang Kang, Aihong Zhong, Ke‐Neng Chen, Nan Wu, Qian Sun, Haitao Ma, Kaican Cai, Changli Wang, Gen Lin, Kunshou Zhu, Yu Zhang, Xiaochun Zhang, Hong Hu, Wengang Zhang, Jun Chen, Zhixiong Yang, Xiaosheng Hang, Jian Hu, Yunchao Huang, Zhiye Zhang, Lumin Zhang, Liwei Zhang, Lunxu Liu, Dongmei Lin, Jie Zhang, Gang Chen, Yuan Li, Lei Zhu, Weihua Wang, Wenbo Yu, Dezhen Cao, Patricia Keegan, Sheng Yao